Vaxart (VXRT)
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized...
- Open
- 0.5395
- High
- 0.5600
- Low
- 0.4996
- Prev. Close
- 0.5150
- Volume
- 363.83K
- Turnover
- 187.89K
- Avg Price
- 0.5164
- Bid/Ask Ratio
- --
- Amplitude
- 11.73%
- 52wk High
- 0.8449
- Volume Ratio
- 1.00
- Turnover Ratio
- 0.15%
Vaxart Analyst Rating
View moreForecast & Rating
Aug 7, 2026Price forecast
$3.33566.00%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 9 at 05:04 AM
Toast Q2 Earnings Call Highlights
- Quartr · Aug 6 at 06:45 PM
VXRT: Positive safety data, BARDA funding, and cash runway into Q2 2027 amid lower revenue
- Market Beat · Aug 6 at 05:41 PM
Vaxart (OTCMKTS:VXRT) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS
- Earnings Watch · Aug 6 at 04:29 PM
Vaxart | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 27.19 M
- PUBT · Jul 30 at 07:08 AM
Vaxart publishes update to financial calendar
- PUBT · Jul 28 at 07:03 AM
Vaxart names Kevin Finney, James Breitmeyer as board committee chairs
